RHA 1, RHA 2, RHA 3, RHA 4 or RHA Kiss? Choosing a Teoxane dermal filler is not simply a matter of matching a syringe to a facial area. The face moves, and different aesthetic objectives demand different gel properties. This UK practitioner guide explains the RHA family, treatment objectives, product differences and safety considerations.
What Is Teoxane RHA?
RHA stands for Resilient Hyaluronic Acid. Teoxane developed its RHA range with facial movement in mind. Lips move during speech, cheeks change shape during smiling and facial tissues respond to expression and ageing. Teoxane's Preserved Network Technology (PNT) is described as retaining aspects of the hyaluronic acid network, supporting the gel properties the manufacturer calls stretch and strength.
The result is a family of distinct formulations, not five interchangeable syringes. The appropriate product depends on the clinical objective, anatomy, patient assessment and current manufacturer instructions for use (IFU).
Understanding Dermal Filler Rheology
Elasticity describes how a gel resists deformation and recovers shape; viscosity concerns resistance to flow; cohesivity concerns how the gel holds together under defined conditions. These properties help explain why fillers behave differently, but no single measurement determines clinical suitability.
A firmer filler is not inherently better, and a flexible filler is not automatically appropriate for every moving facial area. The correct choice is the product whose properties and authorised indications align with the intended correction.
Teoxane RHA 1, 2, 3, 4 and RHA Kiss Compared
| Product | Positioning | Clinical objective |
|---|---|---|
| RHA 1 | Very fine dynamic correction | Fine mobile lines, particularly perioral |
| RHA 2 | Expressive-area correction | Moderate lines and subtle enhancement |
| RHA 3 | Greater support and volume | Deeper folds and pronounced lip volume |
| RHA 4 | Dynamic volumisation | Cheek volume and facial contour |
| RHA Kiss | Dedicated lip refinement | Delicate volume, border definition and shape |
This table compares manufacturer positioning; it is not an injection technique or a substitute for individual product indications.
Teosyal RHA 1: Fine Lines in Highly Mobile Areas
What is RHA 1 designed for?
RHA 1 sits at the finer-correction end of the range. Teoxane positions it for very fine lines in highly mobile facial areas, particularly fine vertical lines above the upper lip. Its high-stretch positioning is relevant when delicate correction and movement are important.
RHA 1 vs RHA 2
RHA 1 is positioned for finer correction; RHA 2 has a broader role when moderate dynamic correction is needed. Neither should be chosen solely by its number.
Teosyal RHA 2: Versatile Expressive-Area Correction
RHA 2 moves towards greater correction while retaining the dynamic positioning of the RHA family. Teoxane identifies expressive areas, including the lips, in its product positioning. It may be considered for moderate dynamic correction or subtle lip enhancement when consistent with the current IFU.
Practitioners should evaluate existing anatomy, movement, prior treatment and the intended aesthetic outcome before selecting it.
Teosyal RHA 3: Deeper Folds and Pronounced Lip Volume
RHA 3 is positioned for deeper lines and folds, particularly around the mouth, and for more pronounced lip volume. Relevant treatment objectives may include selected nasolabial folds, marionette-region concerns and volume enhancement, subject to authorised indications.
RHA 2 vs RHA 3
RHA 2 is generally positioned towards more subtle correction, while RHA 3 addresses deeper folds and greater volume. Patient anatomy and clinical objective matter more than a simplistic ranking of filler strength.
Teosyal RHA 4: Dynamic Facial Volume and Contour
RHA 4 is the most volumising formulation within the RHA 1–4 family. Teoxane positions it for volume and definition in dynamic projected areas, including cheeks and facial contours. Midface assessment should consider projection, existing support, facial movement and previous procedures.
RHA 3 vs RHA 4
RHA 3 is associated with deeper dynamic folds and pronounced lip volume. RHA 4 is positioned for greater dynamic volumisation and facial contour. These are different treatment objectives, not interchangeable placement instructions.
Teosyal RHA Kiss: Dedicated Lip Enhancement
RHA Kiss is positioned for delicate lip volume, shaping and border definition. Patients requesting lip filler may want subtle definition, improved symmetry or greater projection. The request alone does not establish the right formulation.
RHA Kiss vs RHA 2 vs RHA 3 for Lips
RHA Kiss focuses on delicate lip refinement; RHA 2 may be considered for subtle dynamic enhancement; RHA 3 is positioned for more pronounced lip volume. Selection requires consideration of lip anatomy, proportions, movement, prior filler and patient expectations.
Which Teoxane Filler for Which Facial Area?
| Treatment objective | Products to evaluate |
|---|---|
| Fine perioral lines | RHA 1 |
| Moderate dynamic facial lines | RHA 2 |
| Delicate lip refinement | RHA Kiss |
| More pronounced lip volume | RHA 3 |
| Deeper nasolabial folds | RHA 3 |
| Dynamic cheek volume | RHA 4 |
| Deeper structural support | Consider Ultra Deep, outside RHA family |
| Selected tear-trough concerns | Consider Redensity II, outside RHA family |
Important: a facial-area comparison is not an injection map. It does not establish safe injection points, tissue planes, volumes or techniques. Consult the current UK IFU and assess every patient individually.
RHA 4 vs Teosyal Puresense Ultra Deep
Ultra Deep belongs to the wider Teosyal portfolio, not the RHA family. Whereas RHA 4 is positioned for dynamic volume and contour, Puresense Ultra Deep is positioned for deeper structural support and projection. Teoxane discusses Ultra Deep in relation to cheekbone, chin and jawline objectives. Product selection and use must remain IFU-led.
Teosyal Redensity II: Specialist Tear-Trough Filler
Redensity II is not an RHA 1–4 product. It is a specialist Teosyal formulation developed for the under-eye region. 'Dark circles' can reflect hollowing, pigmentation, shadowing, vascular visibility, oedema or skin-quality changes; these do not all respond to filler.
The tear trough is a high-risk anatomical region. Patient selection must account for anatomy, fluid retention, existing filler, medical history and the possibility that filler is unsuitable.
Explore Teosyal Puresense Redensity II
Why Placement Cannot Be Reduced to a Facial Diagram
A product being associated with a facial region does not mean every patient, injection plane or technique is appropriate. Assessment requires individual anatomy, tissue characteristics, medical history, contraindications, previous procedures, facial movement and intended outcome. Practitioners must work within their competence and the manufacturer's instructions.
Dermal Filler Safety and Clinical Governance
Hyaluronic acid fillers can cause bruising, swelling, tenderness, redness, infection, nodules, persistent oedema and delayed inflammatory reactions. Serious complications include vascular occlusion, tissue ischaemia and necrosis; rare vascular events can result in visual loss or other severe injury.
Clinics require appropriate training, informed consent, aseptic practice, documentation, complication recognition, emergency escalation and suitable complication-management protocols. RHA technology does not eliminate the established risks of injectable dermal fillers.
How Long Do Teoxane RHA Fillers Last?
Duration is not identical across the RHA family. Teoxane cites clinical evidence extending up to 18 months for certain RHA 2, RHA 3 and RHA 4 indications. This is not a guarantee for an individual patient. Duration varies with product, indication, anatomy and other patient-specific factors.
Building a Teoxane Formulary for Your Clinic
A considered formulary reflects the treatments the clinic is qualified and equipped to offer. RHA 1 may address fine dynamic concerns; RHA 2 more versatile expressive-area correction; RHA 3 deeper folds and lip volume; RHA 4 dynamic volumisation; RHA Kiss dedicated lip refinement. Specialist products such as Redensity II and Ultra Deep may be relevant to appropriately trained services.
The objective is not to stock every formulation unnecessarily, but to align purchasing decisions with clinical needs, authorised indications and responsible stock management.
Frequently Asked Questions About Teoxane RHA Fillers
What does RHA stand for?
Resilient Hyaluronic Acid, Teoxane's movement-focused hyaluronic acid gel portfolio.
Which Teoxane filler is best for lips?
No single filler is best for every lip. RHA Kiss, RHA 2 and RHA 3 have different positioning; the correct choice depends on patient anatomy, objective and the current IFU.
What is the difference between RHA 2 and RHA 3?
RHA 2 is positioned for moderate dynamic correction; RHA 3 for deeper folds and more pronounced lip volume.
What is the difference between RHA 3 and RHA 4?
RHA 3 is associated with deeper folds and lip volume; RHA 4 with dynamic facial volumisation and contour.
Is Ultra Deep part of the RHA range?
No. Puresense Ultra Deep belongs to the wider Teosyal portfolio.
Is Redensity II an RHA filler?
No. Redensity II is a specialist product within the wider Teosyal portfolio.
Can RHA fillers cause vascular occlusion?
Yes. As with other injectable hyaluronic acid fillers, vascular complications remain possible.
How long does RHA last?
Results vary. Published study outcomes should never be presented as guaranteed treatment duration for every patient.
Buy Teoxane RHA Dermal Fillers From Longeva Pharma
Better product understanding supports better purchasing decisions. Longeva Pharma supports eligible UK aesthetic practitioners with pharmacy-led professional supply.
- Shop Teosyal RHA 1
- Shop Teosyal RHA 2
- Shop Teosyal RHA 3
- Shop Teosyal RHA 4
- Shop Teosyal RHA Kiss
- Shop Teosyal Redensity II
Explore the Longeva Pharma dermal filler collection →
Professional education notice: This article is intended for appropriately trained aesthetic practitioners. It is not injection training and does not replace current manufacturer IFUs, patient-specific assessment, professional standards or complication-management protocols.
Related Longeva Pharma practitioner resources
Explore Toxins and Diluents; Longeva Pharma on Faces; Greater Manchester same-day toxin supply; toxin product and service directory; Faces Consent practitioner guide; practitioner account registration. Prescription-only medicines require appropriate verification, prescribing and dispensing; same-day availability depends on location, timing and stock.